2001PubMedRequires access

[Clinical study of the effect of buflomedil on peripheral neuropathy in diabetic patients].

Mi Zhou, Lei Mx

Open publisher page 0 citations

Abstract

OBJECTIVE: To observe the effect of buflomedil on clinical symptom and nerve conduction velocity (NCV) of diabetic peripheral neuropathy patients. METHODS: 58 cases of diabetic patents with peripheral neuropathy were divided into diabetes group treated with buflomedil (DB) 100 mg.d-1 and diabetes control group (DP) treated with PGE1 200 micrograms.d-1. NCV was measured and peripheral nerve symtom was observed in two groups before treatment and after 2 weeks. RESULTS: NCV and peripheral nerve symptom were obviously improved both in DB group and DP group (P < 0.01). The effective rate were respectively 80.0% and 89.3% in DB group and DP group. The diversity was no significant in DB group and DP group (P > 0.05). CONCLUSION: buflomedil is an effective and safe drug for treating diabetic peripheral neuropathy patients.

About this research paper

What this paper is about

OBJECTIVE: To observe the effect of buflomedil on clinical symptom and nerve conduction velocity (NCV) of diabetic peripheral neuropathy patients. METHODS: 58 cases of diabetic patents with peripheral neuropathy were divided into diabetes group treated with buflomedil (DB) 100 mg.d-1 and diabetes control group (DP) treated with PGE1 200 micrograms.d-1. NCV was measured and peripheral nerve symtom was observed in two groups before treatment and after 2 weeks. RESULTS: NCV and peripheral nerve symptom were obviously improved both in DB group and DP group (P < 0.01). The effective rate were respectively 80.0% and 89.3% in DB group and DP group. The diversity was no significant in DB group and DP group (P > 0.05). CONCLUSION: buflomedil is an effective and safe drug for treating diabetic peripheral neuropathy patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To observe the effect of buflomedil on clinical symptom and nerve conduction velocity (NCV) of diabetic peripheral neuropathy patients. METHODS: 58 cases of diabetic patents with peripheral neuropathy were divided into diabetes group treated with buflomedil (DB) 100 mg.d-1 and diabetes control group (DP) treated with PGE1 200 micrograms.d-1. NCV was measured and peripheral nerve symtom was observed in two groups before treatment and after 2 weeks. RESULTS: NCV and peripheral nerve symptom were obviously improved both in DB group and DP group (P < 0.01). The effective rate were respectively 80.0% and 89.3% in DB group and DP group. The diversity was no significant in DB group and DP group (P > 0.05). CONCLUSION: buflomedil is an effective and safe drug for treating diabetic peripheral neuropathy patients.

Key concepts: Medicine, Peripheral neuropathy, Peripheral, Nerve conduction velocity, Diabetes mellitus, Internal medicine, Diabetic neuropathy, Nerve conduction

Related papers

Back to paper searchBrowse research topicsOriginal source
[Clinical study of the effect of buflomedil on peripheral neuropathy in diabetic patients]. — Research Paper | ScholarLens